SI-BONE

SI-BONE

Founded in 2008 by Mark Reiley, a serial medical-device entrepreneur and orthopedic surgeon, SI-BONE entered the public markets in 2018 with a focused bet on the under-treated sacroiliac joint. The company's origin is tied to Reiley's earlier success with Kyphon, the balloon kyphoplasty pioneer acquired by Medtronic for $3.9 billion in 2007. SI-BONE's thesis rests on clinical data showing the SI joint is the pain generator in 15–30% of chronic low-back-pain patients — a condition often misdiagnosed or ignored by traditional spine surgeons. The company operates from Santa Clara, California, and sells the iFuse implant system across the United States, Germany, the United Kingdom, and additional European markets. SI-BONE's strategy centers on a single-product, high-evidence medical-device model. The iFuse-3D and iFuse-TORQ implants are triangular titanium rods placed across the SI joint to provide immediate fixation and long-term fusion. The company deploys capital primarily through its dedicated direct sales organization, which calls on both orthopedic spine surgeons and interventional pain specialists. Its go-to-market approach relies on proprietary clinical studies — two randomized controlled trials, known as INSITE and SALLY — that have strengthened reimbursement coverage. By 2023, Medicare and major commercial payers covered SI joint fusion for appropriate patients. The company has funded its growth through equity offerings since its IPO, raising follow-on capital in 2019 and 2021 to fund salesforce expansion and product development. SI-BONE has grown its active surgeon base to more than 3,200 physicians, with cumulative procedures exceeding 100,000 as of late 2023. The company does not operate a separate investment vehicle or philanthropic foundation in the family-office sense — it is a pure operating company. Laura Francis, who succeeded founder Mark Reiley as CEO in 2021, previously served as the company's CFO from 2015 to 2021. In November 2023, the company launched an expanded commercial team for the iFuse-TORQ implant, targeting interventional spine physicians specifically, signaling a dual-channel strategy that splits orthopedic and interventional pain call points. SI-BONE's structural differentiator is its single-anatomy focus. Unlike diversified spine companies such as Medtronic, Stryker, or Globus Medical, SI-BONE does not manufacture pedicle screws, interbody cages, or cervical plates. It has built its entire R&D pipeline, clinical data portfolio, and sales training curriculum around the SI joint. This narrow mandate reduces channel conflict with the full-line spine sales reps who dominate most hospitals, while giving the company an unusual depth of clinical reference data for one joint. The firm's governance remains founder-influenced through Reiley's ongoing board role, but day-to-day operational control has transitioned to a professional management team with deep public-company experience.